These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 11571730)
1. Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238. Plonowski A; Schally AV; Koppan M; Nagy A; Arencibia JM; Csernus B; Halmos G Cancer; 2001 Sep; 92(5):1168-76. PubMed ID: 11571730 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238. Plonowski A; Schally AV; Nagy A; Kiaris H; Hebert F; Halmos G Cancer Res; 2000 Jun; 60(11):2996-3001. PubMed ID: 10850448 [TBL] [Abstract][Full Text] [Related]
3. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215. Engel JB; Keller G; Schally AV; Halmos G; Hammann B; Nagy A Clin Cancer Res; 2005 Mar; 11(6):2408-15. PubMed ID: 15788692 [TBL] [Abstract][Full Text] [Related]
4. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses. Koppan M; Nagy A; Schally AV; Arencibia JM; Plonowski A; Halmos G Cancer Res; 1998 Sep; 58(18):4132-7. PubMed ID: 9751625 [TBL] [Abstract][Full Text] [Related]
5. Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238. Plonowski A; Schally AV; Nagy A; Sun B; Halmos G Int J Oncol; 2002 Feb; 20(2):397-402. PubMed ID: 11788908 [TBL] [Abstract][Full Text] [Related]
6. Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1. Engel JB; Schally AV; Halmos G; Baker B; Nagy A; Keller G Cancer; 2005 Sep; 104(6):1312-21. PubMed ID: 16047355 [TBL] [Abstract][Full Text] [Related]
7. Human ovarian cancers express somatostatin receptors. Halmos G; Sun B; Schally AV; Hebert F; Nagy A J Clin Endocrinol Metab; 2000 Oct; 85(10):3509-12. PubMed ID: 11061491 [TBL] [Abstract][Full Text] [Related]
8. In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215. Plonowski A; Nagy A; Schally AV; Sun B; Groot K; Halmos G Int J Cancer; 2000 Nov; 88(4):652-7. PubMed ID: 11058885 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. Plonowski A; Schally AV; Nagy A; Sun B; Szepeshazi K Cancer Res; 1999 Apr; 59(8):1947-53. PubMed ID: 10213505 [TBL] [Abstract][Full Text] [Related]
10. Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice. Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K Breast Cancer Res Treat; 2000 Feb; 59(3):255-62. PubMed ID: 10832595 [TBL] [Abstract][Full Text] [Related]
11. Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238. Kiaris H; Schally AV; Nagy A; Sun B; Szepeshazi K; Halmos G Clin Cancer Res; 2000 Feb; 6(2):709-17. PubMed ID: 10690557 [TBL] [Abstract][Full Text] [Related]
12. Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238. Keller G; Engel JB; Schally AV; Nagy A; Hammann B; Halmos G Int J Cancer; 2005 May; 114(5):831-5. PubMed ID: 15609311 [TBL] [Abstract][Full Text] [Related]
13. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers. Szepeshazi K; Schally AV; Halmos G; Sun B; Hebert F; Csernus B; Nagy A Clin Cancer Res; 2001 Sep; 7(9):2854-61. PubMed ID: 11555603 [TBL] [Abstract][Full Text] [Related]
14. A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice. Kiaris H; Schally AV; Nagy A; Szepeshazi K; Hebert F; Halmos G Eur J Cancer; 2001 Mar; 37(5):620-8. PubMed ID: 11290438 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. Kahán Z; Nagy A; Schally AV; Hebert F; Sun B; Groot K; Halmos G Int J Cancer; 1999 Aug; 82(4):592-8. PubMed ID: 10404076 [TBL] [Abstract][Full Text] [Related]
16. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. Miyazaki M; Nagy A; Schally AV; Lamharzi N; Halmos G; Szepeshazi K; Groot K; Armatis P J Natl Cancer Inst; 1997 Dec; 89(23):1803-9. PubMed ID: 9392622 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Nagy A; Schally AV; Halmos G; Armatis P; Cai RZ; Csernus V; Kovács M; Koppán M; Szepesházi K; Kahán Z Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1794-9. PubMed ID: 9465096 [TBL] [Abstract][Full Text] [Related]
18. In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses. Arencibia JM; Schally AV; Halmos G; Nagy A; Kiaris H Anticancer Drugs; 2001 Jan; 12(1):71-8. PubMed ID: 11272290 [TBL] [Abstract][Full Text] [Related]
19. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. Gründker C; Völker P; Griesinger F; Ramaswamy A; Nagy A; Schally AV; Emons G Am J Obstet Gynecol; 2002 Sep; 187(3):528-37. PubMed ID: 12237622 [TBL] [Abstract][Full Text] [Related]
20. Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Arencibia JM; Bajo AM; Schally AV; Krupa M; Chatzistamou I; Nagy A Anticancer Drugs; 2002 Oct; 13(9):949-56. PubMed ID: 12394258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]